[
  {
    "ts": null,
    "headline": "Biogen Inc. stock underperforms Monday when compared to competitors despite daily gains",
    "summary": "Biogen Inc. stock underperforms Monday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=31b2a31324650d91dad6ea79e7874201488ebdff3c52d9e8f95fb8e69d076d0c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737997620,
      "headline": "Biogen Inc. stock underperforms Monday when compared to competitors despite daily gains",
      "id": 132534957,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock underperforms Monday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=31b2a31324650d91dad6ea79e7874201488ebdff3c52d9e8f95fb8e69d076d0c"
    }
  },
  {
    "ts": null,
    "headline": "Eisai Co., Ltd. - FDA Approves LEQEMBI IV Maintenance Dosing for the Treatment of Early Alzheimer s disease",
    "summary": "TOKYO, CAMBRIDGE - Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration has approved the Supplemental Biologics License Application for once every four weeks...",
    "url": "https://finnhub.io/api/news?id=dd1eea152db726341e8670ee837ab49fe99a9071df680f014f1433952abf4b4f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737975922,
      "headline": "Eisai Co., Ltd. - FDA Approves LEQEMBI IV Maintenance Dosing for the Treatment of Early Alzheimer s disease",
      "id": 132479981,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "TOKYO, CAMBRIDGE - Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration has approved the Supplemental Biologics License Application for once every four weeks...",
      "url": "https://finnhub.io/api/news?id=dd1eea152db726341e8670ee837ab49fe99a9071df680f014f1433952abf4b4f"
    }
  },
  {
    "ts": null,
    "headline": "Sage Rejects Biogen Bid, Launches Review of Alternatives",
    "summary": "Sage Rejects Biogen Bid, Launches Review of Alternatives",
    "url": "https://finnhub.io/api/news?id=7f1a9040f9399865b55776489be150745a519c828f1bf6ecb79bfa659100f033",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737970920,
      "headline": "Sage Rejects Biogen Bid, Launches Review of Alternatives",
      "id": 132534958,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Sage Rejects Biogen Bid, Launches Review of Alternatives",
      "url": "https://finnhub.io/api/news?id=7f1a9040f9399865b55776489be150745a519c828f1bf6ecb79bfa659100f033"
    }
  },
  {
    "ts": null,
    "headline": "Sage rejects Biogen's takeover offer, to explore strategic alternatives",
    "summary": "Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen and added that its board of directors has initiated a process to explore strategic...",
    "url": "https://finnhub.io/api/news?id=62c224d0f341c6cfd59f56d913d96ecabf0807d685077728da9b847335e88e22",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737970114,
      "headline": "Sage rejects Biogen's takeover offer, to explore strategic alternatives",
      "id": 132479461,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen and added that its board of directors has initiated a process to explore strategic...",
      "url": "https://finnhub.io/api/news?id=62c224d0f341c6cfd59f56d913d96ecabf0807d685077728da9b847335e88e22"
    }
  },
  {
    "ts": null,
    "headline": "Biogen, Eisai Get FDA Nod for Leqembi IV Maintenance Dosing",
    "summary": "By Colin Kellaher Biogen and Eisai have won Food and Drug Administration approval of an intravenous maintenance dosing of their Leqembi drug for early Alzheimer's disease. The companies late...",
    "url": "https://finnhub.io/api/news?id=807a50ea0c6a2372c4ebe63ea205fd0ad2ae4f349be31f3f83a4905ea9273fad",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737959454,
      "headline": "Biogen, Eisai Get FDA Nod for Leqembi IV Maintenance Dosing",
      "id": 132478471,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Biogen and Eisai have won Food and Drug Administration approval of an intravenous maintenance dosing of their Leqembi drug for early Alzheimer's disease. The companies late...",
      "url": "https://finnhub.io/api/news?id=807a50ea0c6a2372c4ebe63ea205fd0ad2ae4f349be31f3f83a4905ea9273fad"
    }
  }
]